Back to Peptides

Livagen

Moderate Research

KEDA Tetrapeptide | Liver Bioregulator

Dose 10-20 mg daily
Frequency Daily for 10-20 days per cycle
Cycle 10-20 days
Storage Oral capsules: Room temperature. Injectable reconstituted: 2-8°C refrigerated

Livagen is a Khavinson bioregulator tetrapeptide (KEDA) with significant hepatoprotective and immunomodulatory properties. Structurally similar to Epitalon, it normalizes immune and antioxidant status while restoring liver function in hepatitis conditions. Livagen is best known for its ability to decondense chromatin, activating silent genes including ribosomal genes to boost protein synthesis and cellular activity. Maximum protective effects occur during aging.

Mechanism of Action

Livagen works through direct effects on DNA structure and function. It decondenses chromatin (tightly packed DNA), increasing expression of certain genes and improving the 'youthful' profile of cells. The peptide activates multiple genes in lymphocytes, including previously silent ribosomal genes, boosting protein synthesis and cell activity. It exhibits hepatoprotective effects through normalizing immune and antioxidant status in liver tissue.

Key Benefits

  • Significant hepatoprotective properties
  • Decondenses chromatin to activate genes
  • Restores liver function in hepatitis
  • Normalizes immune status
  • Improves antioxidant status
  • Activates ribosomal gene expression
  • Maximum effects occur during aging
  • Boosts protein synthesis and cell activity
Molecular Weight
432 Da
Chain Length
4 amino acids
Type
Tetrapeptide bioregulator
Amino Acid Sequence
One-letter: KEDA
H₂N
K 1
O ‖ C
N
E 2
O ‖ C
N
D 3
O ‖ C
N
A 4
COOH
Lys
1

Lysine

Position 1

Glu
2

Glutamic Acid

Position 2

Asp
3

Aspartic Acid

Position 3

Ala
4

Alanine

Position 4

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Liver Support

  • Hepatoprotection

    Protects liver tissue through normalizing immune and antioxidant status.

  • Hepatitis Support

    Restores liver functions in both acute and chronic hepatitis models.

  • Liver Fibrosis

    Shows protective properties in liver fibroid induration models.

Anti-Aging

  • Chromatin Remodeling

    Decondenses chromatin to restore youthful gene expression patterns.

  • Age-Related Liver Decline

    Maximum hepatoprotective effects occur during aging.

  • Gene Activation

    Activates silent genes including ribosomal genes for improved protein synthesis.

Immune Support

  • Immunomodulation

    Normalizes immune function alongside liver protective effects.

Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles, often repeated 2-3 times per year.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules
Epitalon

Structurally similar; often combined in comprehensive anti-aging protocols.

synergistic
Glutathione

Both support liver function and antioxidant status.

synergistic
Ovagen

Complementary liver bioregulators with different sequences.

synergistic
Vilon

Different organ targets; can be combined in bioregulator protocols.

compatible
During cycle

Chromatin remodeling and gene expression changes begin

Post-cycle

Effects persist due to epigenetic changes

Weeks-Months

Liver function improvements

Long-term

Cumulative benefits with periodic cycles

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual liver symptoms

Contraindications

  • Active liver emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging
  • Influence of KEDA Tetrapeptide on Organism Physiological Function
    Advances in Gerontology (2020)

    KEDA exhibits hepatoprotective, immunomodulatory, and geroprotective properties with maximum effects during aging.

  • Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People
    Bulletin of Experimental Biology and Medicine (2002)

    Livagen activates chromatin decondensation and multiple genes in aged lymphocytes.

  • Hepatoprotective Properties of KEDA in Hepatitis Models
    Experimental Biology and Medicine (2018)

    KEDA normalizes immune and antioxidant status and restores liver functions in hepatitis.

  • Khavinson Peptide Bioregulators
    Advances in Gerontology (2020)

    Comprehensive review of bioregulator peptides and their epigenetic mechanisms.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.